Basmisanil (RG1662) is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors.
It was under development by Roche for the treatment of cognitive impairment associated with Down syndrome.
As of June 2016, it is no longer studied for this purpose. It has also undergone clinical trials for cognitive impairment in patients with schizophrenia.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | Basmisanil, Basmisanil [INN], (1, 1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone, Basmisanil (RG1662) |
|---|---|
| IUPAC Name | (1, 1-dioxo-1, 4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1, 2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone |
| CAS | 1159600-41-5 |
| Molecular Weight | 445.5 |
| Molecular Formula | C21H20FN3O5S |
| SMILES | CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4 |